OPKO Health, Inc. (OPK)

OPKO Health's stock has experienced volatility and strategic shifts in the past six months. In Q3 2025, OPKO Health reported earnings per share of $0.03, surpassing analysts' estimates, but quarterly revenue decreased by 12.6% year-over-year. The company reset its Q4 2025 outlook to reflect the disposition of its oncology business. OPKO Health agreed to sell certain oncology and related clinical testing assets of BioReference Health to Labcorp for up to $225 million. OPKO Health entered into a collaboration agreement with Entera Bio to advance an oral GLP-1/glucagon tablet candidate for obesity and metabolic disorders. Increased activity within the ModeX development programs led to higher research and development expenses. Q2 2025 saw a significant non-recurring expense of $91.7 million related to a convertible note exchange. OPKO's Board of Directors authorized an additional $100 million for its common stock repurchase program in Q1 2025. As of early 2026, analysts have a "Hold" consensus rating for OPKO Health, with an average price target of $2.28.

Specific information regarding the inherent seasonality of demand for OPKO Health's pharmaceutical products is not explicitly detailed. Demand for BioReference's diagnostic services declined after mid-2023, following the end of the COVID-19 pandemic, due to tightening competition. Sales of Rayaldee have remained within a consistent range over the past nine quarters, suggesting a relatively stable but not significantly growing demand.

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company based in Miami, Florida, operating in the Healthcare sector, specifically in the Drug Manufacturers industry. The company's business is segmented into pharmaceuticals and diagnostics. The pharmaceutical division focuses on developing and commercializing novel therapies, including Rayaldee and Somatrogon (NGENLA). The diagnostics segment, primarily operated through BioReference Health, LLC, offers a wide range of laboratory testing services, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, and women's health.

OPKO Health has a direct operational presence in the U.S., Mexico, Chile, Spain, Ireland, Israel, Ecuador, and France. Through its partnership with Pfizer, NGENLA is marketed in over 50 markets worldwide.

OPKO Health is focused on delivering next-generation solutions for serious diseases and has partnerships with leading pharmaceutical companies. The company has faced challenges including past financial instability, revenue declines, and operating losses. The underperformance of certain drugs like Rayaldee and NGENLA has also been noted. The strategic decision to sell off a significant portion of its diagnostics business indicates a shift in focus but also highlights the challenges faced in that segment. Despite these challenges, the company's robust pipeline in oncology, immunology, and infectious diseases, along with strategic partnerships and efforts to reduce costs, are seen by some as potential drivers for future performance.

OPKO Health, Inc. has 335 institutional owners and shareholders holding a total of 213,828,170 shares. Major institutional owners include Rubric Capital Management LP, BlackRock, Inc., and Vanguard Group Inc. Individuals hold approximately 48.68% of the shares. Phillip Frost, M.D., the Chairman and CEO, and his family trust, Frost Gamma Investments Trust, hold significant influence over the company's ownership and voting power.